Health Technology Assessment

All Items

• Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus

  Mario Boccadoro, Patrizia Berto, Sara Bringhen, Elena Zamagni, Patrizia Tosi, Nicola Cascavilla, Nicola Giuliani, Donato Mannina, Renato Zambello, Francesca Patriarca, Vittorio Montefusco, Mariella Grasso, Francesco Di Raimondo, Massimo Offidani, Maria Teresa Petrucci, Pellegrino Musto

  80-86

• Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

  Roberto Caporali, Roberto Ravasio, Paola Raimondo, Fausto Salaffi

  69-79

• Comments on "Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain"

  David Gomez

  67

• Author’s reply to comments on “Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain”

  Néboa Zozaya

  68

• The Clinical and Economic Benefits of a New Paradigm of HCV Diagnosis and Treatment

  Stefano Fagiuoli, Matteo Ruggeri, Filipa Aragao, Rob Blissett

  58-66

• Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

  Roberto Ravasio, Antonio Costanzo, Silvia Antonelli, Alessia Maiorino, Serena Losi

  53-57

• Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy

  Giovanni Di Minno, Roberto Ravasio

  43-52

• Costs of the management of hemophilia A with inhibitors in Spain

  Santiago Bonanad, María Teresa Álvarez, Ramiro Núñez, José Luis Poveda, Beatriz Gil, Elena Ruíz-Beato, Ana Durán, Yoana Ivanova, Inés Pérez-Román, Almudena González-Domínguez

  35-42

• Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital

  Marco Chiumente, Alberto Russi, Federica Todino, Daniele Mengato, Marina Coppola, Melania Rivano, Angelo Claudio Palozzo, Claudio Jommi

  29-34

• A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen

  Sergio Iannazzo

  14-21

• Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain

  Néboa Zozaya, Almudena González-Domínguez, Natividad Calvente, Rita de la Plaza, Ana Herranz, Antonio Blanes, Miguel Tamayo

  8-13

• Metastatic renal cancer: real-world evidence from a large Italian claims database

  Giulia Ronconi, Letizia Dondi, Carlo Piccinni, Silvia Calabria, Anna Capponcelli, Antonella Pedrini, Maurizio Marangolo, Immacolata Esposito, Carmine Pinto, Nello Martini

  1-7

• Cost of illness of cutaneous squamous cell carcinoma (CSCC)

  Andrea Marcellusi, Chiara Bini, Ketty Peris, Paolo Antonio Ascierto, Francesco Saverio Mennini

  148-153

• Cost-effectiveness and budget impact of a lifestyle intervention to improve cardiometabolic health in patients with severe mental illness

  Anne Looijmans, Frederike Jörg, Richard Bruggeman, Robert A. Schoevers, Eva Corpeleijn, Talitha L Feenstra, Antoinette D.I. van Asselt

  131-138

• Towards standardization of economic evaluation research in the youth psychosocial care sector: A broad consultation in the Netherlands

  Silvia M.A.A. Evers, Carmen D. Dircksen

  117-123

• Factors influencing short-term effectiveness and efficiency of the care provided by Dutch general practice mental health professionals

  Tosca G.R. Vennemann, Ben F.M. Wijnen, Lianne Ringoir, Audry Kenter, Marja J.H. van Bon-Martens, Rob J.M. Alessie, Jasper Nuyen

  139-147

• Mental health economics: the Netherlands experience

  Aileen Murphy, Antoinette D.I. Van Asselt

  115-116

• Cost-effectiveness of adding psychomotor therapy to a multidisciplinary rehabilitation program for chronic pain

  Lia van der Maas, Judith E. Bosmans, Maurits W. van Tulder, Thomas W.J. Janssen

  124-130

• Economic burden of prescriptive inadequacy in the management of osteoarthritis in Italy Il burden economico dell’inappropriatezza prescrittiva nella gestione dell’osteoartrite in Italia

  Michele Basile, Filippo Rumi, Marco Palmeri, Ivano Mattozzi, Lamberto Manzoli, Massimo Mammuccari, Sergio Gigliotti, Roberto Bernabei, Americo Cicchetti

  101-108

• Cost-utility of dalbavancin in patients with non-severe ABSSSI in Italy

  Andrea Marcellusi, Chiara Bini, Maria Assunta Rotundo, Rosario Cultrera, Francesco Saverio Mennini

  92-100

• Erratum in: Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease

  Roberto Ravasio, Roberto Giacomelli, Stefano Bianchi

  91

• Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease Analisi di budget impact di anakinra nel trattamento della Malattia di Still in Italia

  Roberto Ravasio, Roberto Giacomelli, Stefano Bianchi

  72-80

• Patterns of prescription, hospitalizations and costs of herpes zoster in patients at risk, from a large Italian claims database

  Silvia Calabria, Giulia Ronconi, Letizia Dondi, Carlo Piccinni, Antonella Pedrini, Immacolata Esposito, Pierluigi Viale, Nello Martini

  66-71

• Cost-effectiveness analysis of dupilumab for the treatment of severe atopic dermatitis in adults in Italy Analisi costo-utilità di dupilumab per il trattamento della dermatite atopica grave negli adulti in Italia

  Antonio Costanzo, Gianluca Furneri, Rossella Bitonti, Maria Paola Pedone, Francesca Fanelli, Roberta Di Turi

  57-65

• Multidisciplinary approach to psoriasis in the Spanish National Health System: A social return on investment study

  Gregorio Carretero, David Moreno, Almudena González Domínguez, David Trigos, Albert Ledesma, Esther Sarquella, María Merino, Carles Blanch, SROI Psoriasis Group

  50-56